

Special Issue

Clinical Trials of Sarcoma

Message from the Guest Editor

This Special Issue focuses on advancements in clinical trials for sarcoma, a rare and diverse group of cancers arising in connective tissues. Despite significant challenges in treatment due to its heterogeneity, recent breakthroughs in targeted therapies, immunotherapy, and precision medicine are reshaping outcomes for sarcoma patients. This collection invites original research, reviews, and case studies highlighting innovative trial designs, biomarker-driven strategies, and translational approaches. By showcasing cutting-edge developments and collaborative efforts, this Special Issue aims at advancing understanding and fostering new therapeutic strategies to improve survival and quality of life for sarcoma patients worldwide.

Guest Editor

Dr. Patrick Schlegel

University Hospital of Regensburg, Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, 93053 Regensburg, Germany

Deadline for manuscript submissions

25 November 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/225573

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)